Treatment of advanced kidney cancer with the targeted therapy Nexavar® (sorafenib) improves certain symptoms and does not adversely affect quality of life. These results were presented at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO).
Nexavar belongs to a group of drugs called targeted agents. Results presented at the 2006 ASCO meeting suggest that targeted therapies have an important role in the treatment of advanced kidney cancer. Nexavar blocks the growth of cancer cells by inhibiting several biological pathways that are involved in cellular replication and spread.
The effect of Nexavar on survival with advanced kidney cancer is being evaluated in a phase III clinical trial known as TARGETs (Treatment Approaches in Renal cancer Global Evaluation Trial). Preliminary results from this study suggest that compared to a placebo, treatment with Nexavar lengthens survival without cancer progression.
In the current analysis, researchers assessed patient-reported symptoms and quality of life among the TARGETs participants.
- There were no significant differences between the Nexavar group and the placebo group in overall quality of life, physical well-being, emotional well-being, social well-being, or functional well-being.
- There was no significant difference between groups in the overall symptom score.
- Certain symptoms, however, were improved among patients treated with Nexavar. These symptoms included cough, fever, “worry that condition will worsen,” and shortness of breath. Patients treated with Nexavar, however, were more likely to report concern about treatment side-effects than patients treated with placebo.
The researchers conclude that in addition to its beneficial effect on survival, Nexavar relieves certain symptoms and does not adversely affect overall quality of life.
Reference: Dhanda R, Gondek K, Song J et al. A Comparison of Quality of Life and Symptoms in Kidney Cancer Patients Receiving Sorafenib Versus Placebo. Presented at the 2006 ASCO Annual Meeting. Abstract #4534.